Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment

Reuters03-23

Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment

Anavex reported new analyses from the ANAVEX 2-73-AD-004 Phase IIb/III program and its ANAVEX 2-73-AD-EP-004 open-label extension in early Alzheimer’s disease, and said the results were presented at the AD/PD 2026 conference.
MRI biomarker analyses showed a correlation between slowing of brain atrophy and changes on ADAS-Cog13, ADCS-ADL, and CDR-SB.
In the ABCLEAR3 precision-medicine subgroup, the reported R² for the relationship between atrophy slowing and ADAS-Cog13 increased from 0.23 to 0.41.
Long-term data cited by Anavex indicated 77.4 weeks of “time saved” versus an ADNI control group after 144 weeks of treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621077049?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621077049","market":"nz","top_or_hot":-1,"title":"Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Anavex reported new analyses from the ANAVEX 2-73-AD-004 Phase IIb/III program and its ANAVEX 2-73-AD-EP-004 open-label extension in early Alzheimer’s disease, and said the results were presented at the AD/PD 2026 conference.\n        </li>\n<li>\n          MRI biomarker analyses showed a correlation between slowing of brain atrophy and changes on ADAS-Cog13, ADCS-ADL, and CDR-SB.\n        </li>\n<li>\n          In the ABCLEAR3 precision-medicine subgroup, the reported R² for the relationship between atrophy slowing and ADAS-Cog13 increased from 0.23 to 0.41.\n        </li>\n<li>\n          Long-term data cited by Anavex indicated 77.4 weeks of “time saved” versus an ADNI control group after 144 weeks of treatment.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AVXL\">Anavex Life Sciences Corp.</a> published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Anavex reported new analyses from the ANAVEX 2-73-AD-004 Phase IIb/III program and its ANAVEX 2-73-AD-EP-004 open-label extension in early Alzheimer’s disease, and said the results were presented at the AD/PD 2026 conference.\n        </li>\n<li>\n          MRI biomarker analyses showed a correlation between slowing of brain atrophy and changes on ADAS-Cog13, ADCS-ADL, and CDR-SB.\n        </li>\n<li>\n          In the ABCLEAR3 precision-medicine subgroup, the reported R² for the relationship between atrophy slowing and ADAS-Cog13 increased from 0.23 to 0.41.\n        </li>\n<li>\n          Long-term data cited by Anavex indicated 77.4 weeks of “time saved” versus an ADNI control group after 144 weeks of treatment.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AVXL\">Anavex Life Sciences Corp.</a> published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2ZN5n9:1","article_id":"2621077049","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621077049","pubTimestamp":1774265382,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Anavex reported new analyses from the ANAVEX 2-73-AD-004 Phase IIb/III program and its ANAVEX 2-73-AD-EP-004 open-label extension in early Alzheimer’s disease, and said the results were presented at the AD/PD 2026 conference.MRI biomarker analyses showed a correlation between slowing of brain atrophy and changes on ADAS-Cog13, ADCS-ADL, and CDR-SB.In the ABCLEAR3 precision-medicine subgroup, the reported R for the relationship between atrophy slowing and ADAS-Cog13 increased from 0.23 to 0.41.Long-term data cited by Anavex indicated 77.4 weeks of “time saved” versus an ADNI control group after 144 weeks of treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVXL":"Anavex Life Sciences Corp."},"translate_title":"Anavex报告在AD-004早期阿尔茨海默病试验中，口服布拉卡美辛治疗144周后节省了77.4周的时间","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":0.9},"content_text":"Anavex reports 77.4-week time saved with oral blarcamesine in AD-004 early Alzheimer’s trial after 144 weeks of treatment\n    \n\n\n          Anavex reported new analyses from the ANAVEX 2-73-AD-004 Phase IIb/III program and its ANAVEX 2-73-AD-EP-004 open-label extension in early Alzheimer’s disease, and said the results were presented at the AD/PD 2026 conference.\n        \n\n          MRI biomarker analyses showed a correlation between slowing of brain atrophy and changes on ADAS-Cog13, ADCS-ADL, and CDR-SB.\n        \n\n          In the ABCLEAR3 precision-medicine subgroup, the reported R² for the relationship between atrophy slowing and ADAS-Cog13 increased from 0.23 to 0.41.\n        \n\n          Long-term data cited by Anavex indicated 77.4 weeks of “time saved” versus an ADNI control group after 144 weeks of treatment.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621077049","isCrawlerRequest":true}